Overview

Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)

Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
The study is designed to investigate difference in percentage of presentation of atelectasis, bronchiectasis, bronchiolitis obliterans, or consolidation in 6 months after discharge in those treated with a low dose regimen of methylprednisolone initiated with 2 or 4 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin versus a high dose regimen of methylprednisolone initiated with 10 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin.
Phase:
N/A
Details
Lead Sponsor:
Beijing Children's Hospital
Collaborators:
Baoding Children's Hospital
Capital Institute of Pediatrics, China
Children's Hospital of Changchun
Children's Hospital of The Capital Institute of Pediatrics
Shanxi Provincial Maternity and Children's Hospital
Shengjing Hospital
Women and Children's Health Hospital of yinchuan City
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate